A Case of Refractory Cutaneous Sarcoidosis Successfully Treated with Infliximab

Sarcoidosis is an inflammatory granulomatous disease affecting multiple organs with cutaneous sarcoidosis occurring in 25% of patients. There are several treatment options available, but alternative therapies should be considered in patients with refractory disease to standard intervention. Though they are not been FDA-approved for sarcoidosis, TNF-a inhibitors have demonstrated significant therapeutic intervention targeting proinflammatory cytokines involves in pathogenesis of sarcoidosis. Herein, we present a case of refractory cutaneous sarcoidosis successfully treated with infliximab therapy with significant hair regrowth on the scalp.